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Abstract: In recent years, the human microbiota has gained increasing relevance both in research and
clinical fields. Increasing studies seem to suggest the centrality of the microbiota and its composition
both in the development and maintenance of what we call “health” and in generating and/or favoring
(those cases in which the microbiota’s complex relational architecture is dysregulated) the onset of
pathological conditions. The complex relationships between the microbiota and human beings, which
invest core notions of biomedicine such as “health” and “individual,” do concern not only problems
of an empirical nature but seem to require the need to adopt new concepts and new perspectives in
order to be properly analysed and utilized, especially for their therapeutic implementation. In this
contribution we report and discuss some of the theoretical proposals and innovations (from the
ecological component to the notion of polygenomic organism) aimed at producing this change of
perspective. In conclusion, we summarily analyze what impact and what new challenges these new
approaches might have on personalized/person centred/precision medicine.
Keywords: microbiome; health; precision medicine; genomics
1. Introduction
A famous metaphor to describe “life” is the tree. The tree enables to express two life aspects,
that might appear somehow in contrast. On the one hand, each leaf stands for a species, highlighting a
particular unique form according to which “life” manifests itself, thus showing the differences among
living things and justifying the need for classification. On the other hand, each branch, connecting
species, represents the historical trajectory (roughly saying: the phylogeny) recalling the fact that all
living creatures share a common descent and reminding us that our partition of the living world is
not so cutting as we would like. The tension between the necessity to order the living world and the
awareness of its “ramified” unity, is a key feature of biological sciences since their origin [1]. Biological
species are surely grasped and described as distinct one from each other, however not sharply as the
categories that we usually adopt to classify them. Species boundaries are, in many cases, fuzzy rather
than sharp. Indeed, biological species do not exist (in the real world) in the isolation of taxonomical
hierarchies. They are rather intimately connected to each other. Sometimes the nature of this relation
is so intrinsic that is labelled as symbiosis or the reciprocal interdependence of different organisms
(either parasitic or mutualistic). So, human beings and their microbial community can be seen as a
clear example of symbiosis.
However, the fuzziness of biological borders can be considered also from a different angle. New
findings, also made possible by a new theoretical perspective, challenge the notion of symbiosis as
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such and push towards a radical change in the organization of the living world. Life is less linear
and far more intricate than we thought. Recent evidence indicate that horizontal gene transfer, which
is a form of transfer of genetic material that does not occur vertically (from parents to offspring) but
horizontally and therefore it is also called lateral gene transfer [2], can be widespread and a broader
phenomenon than thought (not confined to prokaryotes and thus including eukaryotes). Phylogeny is
no longer only a vertical trajectory and of note, evolution can operate also horizontally. Maybe, a more
suitable metaphor than the tree, describing this aspect of life is constituted by the web. According to
some researchers, individuals belonging to plant or animal species should no longer be considered as
such, that is, as single, distinctive biological forms, but rather as networks of biomolecular interactions,
whose nodes are represented by the host and its associated microorganisms. These networks, to all
effects new categories of biological organization, are called holobionts. Given the nature of these
relationships, the holobionts’ genomes should be treated together and not separately, thus constituting
a hologenome. Such intergenomic associations become so essential that previous models of animal and
plant biology, without this dimension, should be considered, at least, partial and sketchy [3].
The consequences of such a change, that is conceptual before being experimental, have the
potential to radically transform not just the way we use to understand various biomedical phenomena
(such as certain physiological functions or dysfunctions) but also the modalities through which we
could interfere with the very same phenomena (e.g., which therapies).
Given such a new perspective, it should not be surprising that human microbiota (usually meant
the variety of “microbial taxa associated with humans” [4]) has become the pivot of an intense
investigation. The nature and the modalities of these association might vary, depending on the
functions and mechanisms considered, but it is now widely recognized that the relationship between
microbial communities and their host is fundamental both for basic and applied research (especially
biomedical) [5].
New evidence highlight how microbiota plays a key role in human physiology, directly affecting
metabolic pathways, spanning from intestinal to brain activities [6,7]. Indeed, recent findings indicate
how an imbalance in the architecture of intestinal microbial populations might be directly involved in
the development of different medical conditions (from metabolic to mood disorders) shedding new
light on the aetiology of different diseases (such as obesity, asthma, autism spectrum disorders, stroke,
diabetes and cancer) [6] (Figure 1).
Increasing studies suggest that microbiota contributes, in different ways and through different
modalities, to the thin “red line” that separates physiological conditions from pathological ones.
Recently, some researchers have acknowledged the central role of different bacterial populations
and strains in modulating the adaptive immune response, thus affecting, for example, cancer
development [8]. Moreover, a more precise understanding of general microbiota composition,
imbalance among and within bacterial populations and their different localizations (e.g., either gut
residents or oral ones) may offer new hints to understand the origin and the progression of certain
disease and thus new potential tools for a more specific diagnosis [9].
This situation is also due to the magnitude (both functionally and structurally) of microbiota
itself, given that microbial cells in the gut outnumber cells of the host [6]. Microbiota metabolites
and especially SCFAs (Short-Chain Fatty Acids) connect different areas of the organism, through
the mediation of the immune and hormone system, such as the so called gut-brain axis [6,10,11]
suggesting that the crosstalk between the organism and its microbial residents is a crucial factor for
the sustenance of physiological and health conditions. In addition to that, it is imperative to recall
that these microorganisms are no longer localized just in the gut. This can explain why the transition,
within scientific terminology, from “gut flora” to “microbiota” does not coincide just with the need of
a more precise or less restrictive, semantics. Rather, as words count for concepts, such a shift mirrors
the fact that commensal, non-commensal and pathogenic organisms populate (beyond the intestinal
tract) the skin, oral mucosa, lungs and other organs and tissues of the so-called “host organism” [12].
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Finally an important caveat. The growing number of studies on the microbiota has generated
many hopes, expectations but also a sort of expla atory hype, that would make the microbiota the
new keystone for the understa ding of otherwise unexplainable phenomena [13]. This vision is not
only simplistic and reductive but also dan erous. The difficulty in establishing causal directio s
and priorities in biolo y suggests caution and urges us to consider the growing impact of studies
on the microbiota in an ther light. Microbiota is indee central but is a piv tal element among
others. Therefore, i describing and re orting the theoretical proposals concerni g the study and
understanding of the microbiota, it is necessary to remember how the increasing interest on it should
not be taken as privileged one compared to others. Rather, new perspectives on it should be seen as
a way to build new systemic approaches (in which, for example, human and microbial genetics are
considered more closely related). Hopef lly, these systemic approaches would provide a more refine
and adequate basis for personalized medicine
2. Composition and Microbiota Status
Due to computational methods, such as metagenomic sequencing [14], it is now possible to
assess the genetic contribution of bacteria to host’s activities and to obtain a better (although still
not exhaustive and incomplete) estimation of microbial population. To the most recent status of
knowledge, microbial community is constituted by a biomass of 1.5–2.0 kg, mainly composed by
anaerobic Bacteria [6]. According to recent reviews [6,15] the most represented phyla are Actinobacteria,
Bacteroidetes, Firmicutes, Proteobacteria and Verrucomicrobia. The composition diversity and the balance
between different phyla and populations (among and within phyla) may differ from the different
subjects. Nevertheless, these differences, maybe in distinct ways and by distinct means, see some
key functions preserved (such as degradation of some chemicals) in order to display and maintain
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“normal and physiological conditions.” However, it is always very hard to determine what is “normal”
in a biological sense. A thing that might be unfeasible for an individual, could be on average for
another one. As a matter of fact, the complex relationship existing between microbial interactions and
composition and other factors (such as, among the others, the human immune system) is a key factor
to determine not just a more adequate notion of health in general but, also, a more adequate notion of
“personal health” (i.e., its unique conditions). Moreover, as already mentioned, microbiota cannot be
reduced or restricted to anaerobic Bacteria. The very same development of sequencing technologies
revealed that other organisms, less investigated, might have a (more or less impactful) role in this
complex network of interactions. For instance, the term “Mycobiota” [16] has been then coined to
address the fungal component (most of the time composed by not culturable strains) of the general
microbiota. Similar studies have started to be conducted concerning viral genomes [17], sometimes
defined as “Virome”).
In addition, one must not forget that biological landscapes as such are shaped by the interaction
with the environment. This does not refer just to general, external conditions (e.g., the pH) but of
course, involve both dietary and life style habits of the “host” and its genome/epigenome. Both
commensal and non-commensal organisms (among the same or different population and phyla) can
either collaborate or compete to niche construction/shape creating a true, intricate ecosystem. If we
embrace the perspective of the human body as an “ecosystem,” then ecological/relational categories
and new theoretical tools [18,19] will be needed to correctly address this picture (potentially modifying
or updating the notion of health itself).
As a consequence of the microbiota importance in all the aforementioned aspects of humans
biology, several scholars and scientists have elaborated new ways and proposals to adequately address
this archetype. In this review we want to examine these different proposals (from the missing organ
hypothesis to the polygenomic organism), which have been developed with the purpose of elaborating
conceptual tools that could account for the current developments of scientific investigations. In fact,
some of the last recent research directions have highlighted that central concepts of contemporary
biology such as organism, organ, symbiosis and so forth, seem to be no longer perfectly adequate,
given the time of their formulation, to account for the latest findings and discoveries produced by
experimental work. This set of theoretical elaborations, which we will briefly present here, appears
central and actually responds to a twofold movement. On the one hand, as mentioned, new concepts
are necessary in order to be able to describe and substantiate, more accurately, the new types of
phenomena that research discovers. On the other hand, a new conceptual and theoretical equipment is
precisely what makes the discovery and classification of new phenomena possible.
3. Microbiota: the Missing Organ
Due to its relevance for human health and physiology, some researchers have proposed to refer to
microbiota as a “missing organ” of human body [20–23]. Far from being just an analogy or a working
metaphor, these authors declare that there are strong reasons to look at microbiota as a true organ.
From a functionalist perspective, it is argued that human constitution is already made by interactions
with cells of different types (and subtypes), displaying diverse, type-associated, activities.
Moreover, the investigation into the formation of eukaryotic cells strongly suggests a relationship
with mitochondrial origin and evolution. Famously, mitochondria are sub-cellular organelles essentially
to provide chemical energy (in the form of ATP) to eukaryotic cells. Nevertheless, in recent years,
it has been shown that mitochondria are also involved in other, crucial, cellular activities, such as
metabolism of both amino acids and nucleotides, fatty-acid assimilation, protein synthesis, forms of
programmed cell death (e.g., apoptosis) and the regulation of various homeostatic factors [24]. However,
the fascinating detail is that phylogenetic analyses indicate mitochondria having a prokaryotic origin,
thus showing that a fundamental eukaryotic cell compartment has an endosymbiotic provenance.
The presence of elements, once exogenous, in the constitution of eukaryotic organisms, should make
us reflect on the notions of “identity” and “unity” of biological entities. Accordingly, it should not be
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strange to look at microbiota as a legitimate part of “humans” as organisms (this somehow implies that
if we want to adopt the elusive notion of “human nature,” the microbiota would definitely contribute
to it).
The property of being an organism (a central notion in biology [25] is generally associated with the
capacity of reproducing within a given specific lineage. Homo sapiens (whose genome includes also
mitochondrial genome) lineage is notoriously transmitted by vertical descent. However, as recently
highlighted, the transmission of the human microbiota to the progeny can also occur through other
modalities, less specific but still reproducible. In this way there is the possibility of inheriting
a microbiota constituted by a coherent base, specified into inter-individual variations, which are
preserved throughout the generations inside a parental line [20]. From this perspective, the various
forms of physical-chemical interactions between microbiota and its “host” are so deep-rooted and
integrated, that considering microbiota as merely external, just because of the genomic differences,
seems, at least, questionable. First, the human genome itself displays the vestiges (now fully part of
what we call “human”) of past infections and interactions with other organisms (such as the famous
Human Endogenous Retro Viruses - HERVs) [26]. Second, the magnitude of activities of the microbiota
itself can be genuinely seen comparable to those of a traditional organ [23]. This is also why other
authors [27] have proposed to classify (with an eye towards possible manipulation/modification for
biomedical purposes in the light of health problems) microbial populations according to functional
criteria (rather than just phylogenetical). This type of move, not free of problems [28], is somehow
motivated by the need of finding how (e.g., in which ways and how much) microbial activity contributes
to host functionality despite the distinct genomic origins.
If this is the case, further studies might have the potential to revolutionize entire areas of clinical
investigations and the rationale of many health-care strategies. Indeed, certain future therapeutic
interventions could be directed to the “new physiological” pathways. Drugs could be designed to
address interactions within the “missing organ” itself or with the other ones. As some researchers
argue, if medicine has historically been developed through specialties based on organs or organ
systems (think of cardiology, pneumology or gastroenterology), it would not be strange to think of a
future development of a specific branch such as “microbiomology” or “clinical microbiology.” Such a
specialty, starting from the consideration of the structure of the microbiota as an actual organ, would
study its physiology and pathology, keeping an eye to its relevance both in diagnostics and preventive
medicine. [20].
4. Beyond the Symbiosis and The Missing Organ: the “Holobiont”
By considering the countless interactions between the host and its microbiota (however differently
composed) either as a symbiosis or as a relationship between an organism and one of its organs is still
far from a radical conceptual change that some scientists are proposing in addressing these issues.
As already mentioned in the introduction, a completely distinct view that challenges both
the theoretical and the experimental side is constituted by the notions of holobiont and hologenome.
According to this perspective [3], we should stop at seeing symbiosis as an interaction (no matter
how complex or peculiar) of different organisms (such as the “host” and its commensal associated
species) but rather as a complex unity of biological organization (as much as the organism itself)
that should be considered as the privileged one. The specificity of this viewpoint is that, contrary
to the traditional notion of symbiosis, which is basically an extension of the current understanding
concerning these phenomena, the notions of holobiont and hologenome challenge the contemporary
conceptual view. They do so by offering not just a different angle from which one should look at these
phenomena but a deconstruction of the categories according to which we consider those “things,”
precisely our phenomena on interest (i.e., the system we want to investigate). Moreover, such a change
of prospect will inevitably provide different categories and, as a consequence of that, a different
experimental possibilities. As François Jacob famously argued, the work of the biologist necessarily
starts with the choice of an operative framework, defined as the “experimental system.” According to
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Jacob, all depends from this initial decision: the type of experiments that can be conducted but also
the type of legitimate hypotheses that can be formulated and therefore also the type of answers the
scientist can obtain [29]. According to this sense, due to their hybrid nature (in between organisms and
communities) [30], holobionts and hologenomes might have the potential to become a “New System.”
Bordenstein and Theis [3] also provide a list of key points in order to clarify the holobiont
perspective and to avoid misconceptions about it.
First, as already mentioned, holobionts and hologenomes can be seen as units of biological
organization. This immediately embeds an ecological perspective in the study of molecular interactions.
Being a unit of biological organization means to understand that organisms do not exist in isolation.
From a functional point of view, their existence, development, evolution are intrinsically shaped by
the reciprocal interaction and by the relation with the environment (both organic and not organic).
For instance, one can see a virus as simply as a sequence of either DNA or RNA within a protein
capsid. But from a different viewpoint, let us call it a processual view, the perspective of biological
organization around units formed by different organisms and their genomes, that virus is now a part
of interconnected system to which it will contribute in terms of physiology, development, function
or dysfunction.
Second, it is important not to mistake holobionts and hologenomes for organs, super-organisms
or metagenomes. Indeed, on one hand, organs and super-organisms both share the same genomes,
while on the other, the term metagenome simply states that there is something more than the genome
but clearly does not take into account the interactive/organismic/ecological perspective, which is at
the core of holobiont and hologenome conceptualization (as the “disunity” of the holobiont brings
important features as much as its unity [30]).
Third, the netlike nature of hologenome suggests that all the genomes involved should be
considered. Moreover, being hologenomes a multiplicity of genomes (nuclei, organelles, bacteria, fungi
and viruses), variations and mutations can occur at any level of the network and might have an impact
on the entire organizational unit. In addition, since such units could be the target of evolutionary
change, this change in perspective might also affect our perception and conceptualization of the
evolutionary process itself. This should not be taken in a radical, superficial or simplistic way, meaning
that we need to abort the evolutionary theory. Rather, both hologenomes and holobionts challenge a
particular interpretation of evolutionary change, the so-called “neo Darwinian framework,” which
neglects any form of plasticity or porosity within the genome itself. On the contrary, by adopting
a view closer to, the so called, “extended synthesis” [31,32], both inheritance and different forms of
genetic transmissions such as horizontal gene transfer [2] (which is now documented also between
prokaryotes and eukaryotes) as well as the incorporation of environmental elements, should be now
fully considered.
5. Holobionts, Faecal Transplantation and Bacteriotherapy.
The holobiont perspective is particularly intriguing (and challenging) when specific therapeutic
interventions concerning the microbiota are considered. Nowadays, Faecal Microbiota Transplantation
(FMT) is a quite established therapeutic intervention, famously adopted to treat infection with
Clostridium difficile [33,34] In the wake of this success, it has been suggested that the microbiota
could be seen and adopted as a real therapy, a bacteriotherapy [33], also in other pathological conditions.
Again, from a conceptual point of view, this approach poses this type of intervention as a hybrid,
in between “organ transplantation” and “immunotherapy.”
From the holobiont perspective the possibility to use microbiota as a therapy (and a personalized
one, see also section 8) can be seen as a way to re-establish/reinforce either the structure or the
efficiency of a network whose functionality and shape are at core of the global health of the system.
Thus, several approaches may be adopted to pursue this scope (mimicking traditional strategies).
On the one hand, dietary and lifestyle interventions (e.g. probiotics, prebiotics, other nutraceutical
compounds) can directly modulate the composition and the functionality of microbiota [35–38]. Other
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approaches involve a genetic manipulation of microbiota itself [36,39,40]. In this case the idea is to
use genetically modified strains of bacteria in order not only to act as ad hoc therapy but also in the
preventive phase, as tools to diagnose specific pathologies. By trying to intervene on the network
(i.e., intervening on the holobiont), this approach has the potential of being more effective, more
coordinated and, at the same time, less invasive and less expensive compared to current methods [39].
However, despite the coherence of the hypothesis, the novelty of the field and the consequent lack
of knowledge both pose some difficulties that cannot be forgotten. As a matter of fact, an increasing
number of studies do suggest that the microbiota is directly involved in the metabolic syndrome,
showing a role in determining key factors such as insulin resistance or blood pressure [33]. Nonetheless,
at the moment, only few researches show sufficiently robust data to legitimize a direct causal link
(on which researchers and clinicians might operate). Therefore, some researchers have highlighted
the need to investigate these relationships through new studies (including RTCs) that require greater
attention to the specific bacterial strains involved, to the changes in their metabolites, trying to clarify
how the genetic and epigenetic aspects of the microbiota and the host will influence each other
(of course the relationship with the immune system is central here) [10,13,33].
Moreover, as recently reported and coherently with the holobiont perspective, the microbiota
appears to be deeply personalized, showing a high inter-variability among different subjects (also, due
to dietary diversities, showing variations among cultures and geographical regions) and important
fluctuations during diverse phases of the day [13]. In addition, in case of genetically engineered
microbiota, despite their designed precision, the impact of their introduction on the entire network
(with possible unwanted effects) still needs to be fully addressed and evaluated.Nevertheless,
these difficulties should not discourage further scientific investigations. In the recent years we have
understood that the interactions between the elements and the components of that system that is
our organism (and on this see also section 6) are more complex than we thought. At the same
time, this awareness shows us the need for a new systemic viewpoint (and the limitation of purely
reductionist approaches). The fact that many aspects of this perspective are still obscure is precisely a
reason to conduct more research into it.
6. The Polygenomic Organism
The increasing interest towards microbiota and its interactions (whose modalities are still widely
unknown) and the rise of new concepts such as holobionts and hologenomes (to deal with the netlike
nature of these phenomena) urge us to critically address the notion of organism itself which was
already at the centre of conceptual change in biology [25,41]. However, this is not because of a highly
theoretical, speculative exercise (that, nevertheless, will be interesting in itself). Rather, by reconsidering
fundamental notions at the core of the theoretical apparatus we adopt to deal with disease and health
we might find new ways to approach issues that really matter from a practical point of view.
A first way to challenge the current concept of organism is the assumption of individual genetic
homogeneity. According to some scholars this idea is decidedly deceptive. In fact, such a view
constitutes the basis of a series of misunderstandings concerning the characteristics of those systemic
entities, usually called as “organisms [42].
The first critical element of genetic homogeneity is understanding that in both natural and
artificial processes we see a significant degree of chimerism and mosaicism in many, not to say almost
all, multicellular organisms, including humans. The degree of similarity in this context seems to be
fuzzier than previously described. Therefore one may argue that the hypothesis according to which
every cell of an organism has the same genome of another one could be, at least, an oversimplification
of a more intricate picture [42].
A second layer is constituted by epigenetics. Epigenetics has shown that, even if genomes of cells
within an organism will be somehow homogeneous in their constitution, the way in which genes
and other functional elements of a genome are expressed is far from being the same. Rather, such a
diversity in expression and regulation provides also an explanation of different cell types [42].
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By following these suggestions, it is possible to conceive that entities we classify as living unities
might not be those identified by our traditional notion of species and organisms. For instance,
the phenomenon of chimerism challenges our ideas about the consistency of organisms themselves.
Moreover and maybe more dramatically, the profound interactions and interconnections among living
beings normally considered members of the different species or lineages. Of course, the change of
perspective is not meant to determine which should be the right way to divide and classify the living
world. Rather, it suggests that different approaches might reveal connections and causal relations that
may result intrinsically hidden, according to other ways of partitioning the living world.
As is well argued by Dupré, the different elements of a cell can “co-operate” in a rather
complex way. In some cases, the combination of different communities of different species of
microorganisms gives rise to real diversified and separate lineages (such as mitochondria). In other
cases, the cooperation characterizes phenomena of even higher complexity (the case of multicellular
organisms) and we face real systemic units, composed of different entities, interacting together in
a synergistic way. A situation so complex and articulated between cooperative and competitive
processes, will also require that different research interests, bearers of different questions, would be
and should be prosecuted. It is not bizarre to think that such research directions will produce new
ways of delimiting and distinguishing biological individuals and their boundaries, or at least to believe
they will deeply question those currently employed [42].
7. Microbiota and Health: the Ecological Perspective and New Research Directions
If we take all these perspective seriously, it is hard not to believe that they are going to affect other
notions, central to both research and clinical investigation. If the notion of biological individual will
be modified (or at least updated), also the concept of health itself may face a radical change. In other
words, if we move from the conception of individuals as punctiform units to the view that what we
call individuals are rather peculiar intertwined networks, or sophisticated micro-ecosystems, the idea of
health seems to acquire a more ecological nuance [43], also suggesting a complex system of health levels
in which that individual health cannot be fully detached from “healthy conditions” of other layers
into play.
This is not just in theory. In the last years, several promising, interdisciplinary approaches have
been developed to translate an ecological perspective into research and clinical practices. For instance,
in the case of cancer, increasing studies suggest how it should be considered as a multifactorial
disease [44,45]. This is due to the fact that a large number of endogenous and exogenous factors (such
as diet, exposure to certain environments, lifestyles) and their peculiar (most of the time personalized)
combination, can give rise to the conditions for the development of the disease.
In this respect, immunotherapy represents a promising action line. However, if the microbiota is
actually considered as a functional part of the immune system itself and thus, the immune response
is a network-based, environmental feature, the ecological perspective becomes central in analyzing
the immune response in the tumour microenvironment [45]. Moreover, if we embrace a network
perspective on health (such as the holobiont view) the distinction of exogenous and endogenous
becomes less neat and less sharp.
The emerging field of molecular pathological epidemiology (MPE) constitutes a promising research
agenda in this direction, by creating a hybrid field between pathology and data science [46,47].
This approach promotes a view that combines various potential risk factors (the epidemiological
point of view) with molecular pathology [47]. Accordingly, any disease can be phenotyped, based on
pathogenic mechanisms. A research based on MPE can determine a better understanding of pathogenic
landscape and evaluate how an association is depth and intense for given subtypes. Unlike traditional
epidemiological research, this approach may help detecting causal connections [46]. This is particularly
relevant, given that microbiota’s activities and functions, by playing potential diverse (protective or
risk) factors, can be finally seen in the web of causal connections, thus determining the overall health
status of the network.
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Given the current scope of personalized/precision biomedicine in treating the individual, rather
than disease, the transformation foreseen here may also change the strategies we adopt in dealing with
a various number of pathologies, still not fully curable or treatable.
8. Precision Medicine/Personalized Medicine: the Individual and the System
In the last years, the health care system has rapidly changed. Both newspapers and specialized
press report and hail the new era of personalized, stratified, person-centred, precision medicine
(Figure 2). Indeed, these expressions are often used interchangeably [48]. This semantic blurriness [49]
mirrors economic, institutional solutions and approaches, aiming at the establishment of a new
paradigm for health care systems.
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pathogenic landscape and evaluate how an association is depth and intense for given subtypes. 
Unlike traditional epidemiological research, this approach may help detecting causal connections 
[46]  This is particularly relevant, given that microbiota’s activities and functions, by playing potential 
diverse (protective or risk) factors, can be finally seen in the web of causal connections, thus 
determining the overall health status of the network.  
Given the current scope of personalized/precision biomedicine in treating the individual, rather 
than disease, the transformation foreseen here may also change the strategies we adopt in dealing 
with a various number of pathologies, still not fully curable or treatable. 
8. Precision Medicine/Personalized Medicine: the Individual and the System 
In the last years, the health care system has rapidly changed. Both newspapers and specialized 
press report and hail the new era of personalized, stratified, person-centred, precision medicine 
(Figure 2). Indeed, these expressions are often used interchangeably [48]. This semantic blurriness 
[49] mirrors economic, institutional solutions and approaches, aiming at the establishment of a new 
paradigm for health care systems. 
  
Figure 2. Definition of personalized, stratified, person-centred, precision medicine. We have fine
defined these expressions that are often used interchangeably.
Spanning from the molecular understanding of biological phenomena to the implement of
computational resources to study the general behaviour of living systems, precision medicine is normally
conceived to embed an integrated, multidisciplinary approach, that should combine different kinds of
data (from genomic analyses to environmental studies) in order to create a health care model tailored
on the individual patient [50]. On the other hand, new approaches and techniques have fostered the
division of population into many subgroups, which eventually need different and specific treatments
(the so-called stratified medicine), thus paving the way to the decomposition of the universality of
human kind, into a myriad of unique variants that will be able to detect individual specificities and
therapeutically address them: personalized medicine.
Despite this terminological struggle, what is at stake here is the individuation of those features
that contribute to the creation of medical model that should be more predictive, more preventive
and more personalised (also in the sense of paying more attention to those aspects, cultural, ethical
and psychological, often neglected by the clinic dimension). Therefore, a Predictive, Preventive and
Personalised Medicine (PPPM) [50] will try to focus on diverse layers and aspects that contribute to
dissect the notions of individual, health and disease and relative interventions. Thus, according to
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this perspective, both genetics and epigenetics, life style and related activities (such as diet and sport),
socio-economic conditions, cultural belonging and psychological setting (all elements on which the
impact of microbiota can be critical and cannot be mistreated) should all receive full consideration in a
commonly framed manner [50]. Moreover, other aspects such as translational research, information
technology and public dissemination of scientific and clinical results, biolaw and education will take
part into the new model.
At first glance big data analyses granted by computational/omics methods seem to go in the
direction of fostering this approach through the capacity to deal with data and information coming
from various sources. However the situation might not be so optimistic. The case of precision oncology
is somehow emblematic. In a recent issue on Nature, the haemato-oncologist Vinay Prasad has
revealed that a large number of cancer patients has not benefited from the so-called precision medicine.
Although the genome of a large number of patients (tens of thousands) has been already sequenced,
the number of interesting or significative cases remains extremely low. Moreover, this approach does
not seem to have shown that it can improve the results in controlled studies. Therefore precision
oncology remains, as such, an approach still waiting to be corroborated and established [51]. How is
it so?
Here of course we cannot and should not provide a technical answer. However it seems that
profiling patients, in the light of precision/personalized medicine approaches, does not provide what
has been thought to promise, probably due to the fact that the “complexity” of a patient’s individuality
(affecting also its clinical condition) may not and cannot be simply reduced to the collection of its data
(or represented by it), no matter how much precise and rigorous such analysis can be. This is not to
say that computational strategies employed by precision-oncology are useless. On the contrary, beside
the information they provide concerning human genetic variants and stratification, they were also
extremely important in revealing that personalization of healthcare (both in terms of precision and
consideration of specific patient needs) cannot be done simply by enlarging the amount of data nor the
sources of data. The determinants of individual health, which contribute to the specific identity of a
single patient, cannot be fully and correctly understood just in terms of omics analysis.
By considering what has been said, it seems that biomedicine is facing a sort of paradox. On the
one hand, both scientific understanding and patients’ needs push towards a focus on the individual.
On the other hand, research findings suggest that the decomposition of biological phenomena and
their (so-called) reductionist analysis are only methodological and require more and more a systemic
perspective in order to be adequately addressed and explained [52]. In addition, not only does
traditional medical taxonomy (organ based) seem no longer suitable to fully appreciate the novelties
of current scientific understanding of disease and health (and thus the potential therapies) [53] but the
patient themselves, the biological entities that are the biomedicine focus, cannot longer be seen just as
single units or “monads,” bottom-layers of individualization.
In this respect, we propose that the advancement of the studies on the microbiota (both
conceptual and empirical) may suggest a way to reconcile diverse perspectives and somehow to
“solve” the paradox. Indeed, by looking at individual patients as networks of different but nevertheless
fundamental, components it could be possible to start thinking and designing new systemic approaches
for therapy that will be tailored but not reductionist. By forcing us to see human beings as ecosystems,
these studies will help, somehow surprisingly, to better understand the individual patient and, at the
same time, they will fully acknowledge that those individuals are also, by some means, a “multitude.”
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